Generics in Turkey industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in Turkey
Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in Turkey
Leading company profiles reveal details of key generics market players’ global operations and financial performance
Add weight to presentations and pitches by understanding the future growth prospects of the Turkey generics market with five year forecasts by both value and volume
Essential resource for top-line data and analysis covering the Turkey generics market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.
Reasons To Buy
What was the size of the Turkey generics market by value in 2016?
What will be the size of the Turkey generics market in 2021?
What factors are affecting the strength of competition in the Turkey generics market?
How has the market performed over the last five years?
How large is Turkey’s generics market in relation to its regional counterparts?
For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
The Turkish generics market is expected to generate total revenues of $1.8bn in 2016, representing a compound annual growth rate (CAGR) of 6.2% between 2012 and 2016.
Market consumption volume is forecast to increase with a CAGR of 0.1% between 2012 and 2016, to reach a total of 51.4% of total pharma volume in 2016.
In 2012, the Turkish government decided to provide free access to healthcare services for those earning less than roughly $150 per month, whilst those earning more paid a social security premium.